All patients received transdermal estradiol ( 100 g/d ) plus oral medroxyprogesterone acetate 10 mg/d ( 12 d/mo ) for a 3-month run-in period before being randomized in a double-blinded fashion to the addition of transdermal T ( 150 g/d ) or placebo .